Search Results - "Lehmann, Soren"

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Juliusson, Gunnar, Antunovic, Petar, Derolf, Åsa, Lehmann, Sören, Möllgård, Lars, Stockelberg, Dick, Tidefelt, Ulf, Wahlin, Anders, Höglund, Martin

“…Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit for intensive treatment because of the risk of fatal…”
Get full text

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer by LEHMANN, Sören, BYKOV, Vladimir J. N, PAUL, Christer, WIMAN, Klas G, ANDERSSON, Per-Ola, ALI, Dina, ANDREN, Ove, CHERIF, Honar, TIDEFELT, Ulf, UGGLA, Bertil, YACHNIN, Jeffrey, JULIUSSON, Gunnar, MOSHFEGH, Ali

“…APR-246 (PRIMA-1MET) is a novel drug that restores transcriptional activity of unfolded wild-type or mutant p53. The main aims of this first-in-human trial…”
Get full text

Characterization and prognostic features of secondary acute myeloid leukemia in a population‐based setting: A report from the Swedish Acute Leukemia Registry by Hulegårdh, Erik, Nilsson, Christer, Lazarevic, Vladimir, Garelius, Hege, Antunovic, Petar, Rangert Derolf, Åsa, Möllgård, Lars, Uggla, Bertil, Wennström, Lovisa, Wahlin, Anders, Höglund, Martin, Juliusson, Gunnar, Stockelberg, Dick, Lehmann, Sören

“…Patients with secondary acute myeloid leukemia (AML) often escape inclusion in clinical trials and thus, population‐based studies are crucial for its accurate…”
Get full text

Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications by Nilsson, Christer, Linde, Fredrika, Hulegårdh, Erik, Garelius, Hege, Lazarevic, Vladimir, Antunovic, Petar, Cammenga, Jörg, Deneberg, Stefan, Eriksson, Anna, Jädersten, Martin, Björkvall, Cecilia Kämpe, Möllgård, Lars, Wennström, Lovisa, Ölander, Emma, Höglund, Martin, Juliusson, Gunnar, Lehmann, Sören

“…Studies of therapy-related AML (t-AML) are usually performed in selected cohorts and reliable incidence rates are lacking. In this study, we characterized,…”
Get full text

Expression levels of long non-coding RNAs are prognostic for AML outcome by Mer, Arvind Singh, Lindberg, Johan, Nilsson, Christer, Klevebring, Daniel, Wang, Mei, Grönberg, Henrik, Lehmann, Soren, Rantalainen, Mattias

“…Long non-coding RNA (lncRNA) expression has been implicated in a range of molecular mechanisms that are central in cancer. However, lncRNA expression has not…”
Get full text

A risk score based on real-world data to predict early death in acute promyelocytic leukemia by Österroos, Albin, Maia, Tânia, Eriksson, Anna, Jädersten, Martin, Lazarevic, Vladimir, Wennström, Lovisa, Antunovic, Petar, Cammenga, Jörg, Deneberg, Stefan, Lorenz, Fryderyk, Möllgård, Lars, Uggla, Bertil, Ölander, Emma, Aguiar, Eliana, Trigo, Fernanda, Höglund, Martin, Juliusson, Gunnar, Lehmann, Sören

“…With increasingly effective treatments, early death (ED) has become the predominant reason for therapeutic failure in patients with acute promyelocytic…”
Get full text

A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo by Arruda, Lucas C M, Stikvoort, Arwen, Lambert, Melanie, Jin, Liqing, Rivera, Laura Sanchez, Alves, Renato M P, De Moura, Tales Rocha, Mim, Carsten, Lehmann, Sören, Axelsson-Robertson, Rebecca, Dick, John E, Mattsson, Jonas, Önfelt, Björn, Carlsten, Mattias, Uhlin, Michael

“…Less than a third of acute myeloid leukemia (AML) patients are cured by chemotherapy and/or hematopoietic stem cell transplantation (HSCT), highlighting the…”
Get full text

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period by Juliusson, Gunnar, Hagberg, Oskar, Lazarevic, Vladimir Lj, Ölander, Emma, Antunovic, Petar, Cammenga, Jörg, Wennström, Lovisa, Möllgård, Lars, Brune, Mats, Jädersten, Martin, Deneberg, Stefan, Lehmann, Sören, Derolf, Åsa Rangert, Höglund, Martin

Get full text

Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells by Hultmark, Simon, Baudet, Aurélie, Schmiderer, Ludwig, Prabhala, Pavan, Palma-Tortosa, Sara, Sandén, Carl, Fioretos, Thoas, Sasidharan, Rajkumar, Larsson, Christer, Lehmann, Sören, Juliusson, Gunnar, Ek, Fredrik, Magnusson, Mattias

“…Combination treatment has proven effective for patients with acute promyelocytic leukemia, exemplifying the importance of therapy targeting multiple components…”
Get full text

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies by Herold, Nikolas, Rudd, Sean G, Ljungblad, Linda, Sanjiv, Kumar, Myrberg, Ida Hed, Paulin, Cynthia B J, Heshmati, Yaser, Hagenkort, Anna, Kutzner, Juliane, Page, Brent D G, Calderón-Montaño, José M, Loseva, Olga, Jemth, Ann-Sofie, Bulli, Lorenzo, Axelsson, Hanna, Tesi, Bianca, Valerie, Nicholas C K, Höglund, Andreas, Bladh, Julia, Wiita, Elisée, Sundin, Mikael, Uhlin, Michael, Rassidakis, Georgios, Heyman, Mats, Tamm, Katja Pokrovskaja, Warpman-Berglund, Ulrika, Walfridsson, Julian, Lehmann, Sören, Grandér, Dan, Lundbäck, Thomas, Kogner, Per, Henter, Jan-Inge, Helleday, Thomas, Schaller, Torsten

“…The therapeutic response of acute myelogenous leukemia to the nucleoside analog ara-C is controlled by SAMHD1, an enzyme that hydrolyzes the activemetabolite…”
Get full text

Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation by Rönnerblad, Michelle, Andersson, Robin, Olofsson, Tor, Douagi, Iyadh, Karimi, Mohsen, Lehmann, Sören, Hoof, Ilka, de Hoon, Michiel, Itoh, Masayoshi, Nagao-Sato, Sayaka, Kawaji, Hideya, Lassmann, Timo, Carninci, Piero, Hayashizaki, Yoshihide, Forrest, Alistair R.R., Sandelin, Albin, Ekwall, Karl, Arner, Erik, Lennartsson, Andreas

“…In development, epigenetic mechanisms such as DNA methylation have been suggested to provide a cellular memory to maintain multipotency but also stabilize cell…”
Get full text

Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells by Palau, Anna, Segerberg, Filip, Lidschreiber, Michael, Lidschreiber, Katja, Naughton, Aonghus J., Needhamsen, Maria, Jung, Lisa Anna, Jagodic, Maja, Cramer, Patrick, Lehmann, Sören, Carlsten, Mattias, Lennartsson, Andreas

“…Isocitrate dehydrogenase (IDH) mutations are found in 20% of acute myeloid leukemia (AML) patients. However, only 30–40% of the patients respond to IDH…”
Get full text

RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia by Anande, Govardhan, Deshpande, Nandan P, Mareschal, Sylvain, Batcha, Aarif M N, Hampton, Henry R, Herold, Tobias, Lehmann, Soren, Wilkins, Marc R, Wong, Jason W H, Unnikrishnan, Ashwin, Pimanda, John E

“…RNA splicing is a fundamental biological process that generates protein diversity from a finite set of genes. Recurrent somatic mutations of splicing factor…”
Get full text

Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective by Moreno Berggren, Daniel, Garelius, Hege, Willner Hjelm, Petter, Nilsson, Lars, Rasmussen, Bengt, Weibull, Caroline E., Lambe, Mats, Lehmann, Sören, Hellström-Lindberg, Eva, Jädersten, Martin, Ejerblad, Elisabeth

“…In this population-based study, we aimed to characterize and compare subgroups of therapy-related Myelodysplastic syndromes (t-MDS) and define the implications…”
Get full text

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register by Moreno Berggren, Daniel, Folkvaljon, Yasin, Engvall, Marie, Sundberg, Johan, Lambe, Mats, Antunovic, Petar, Garelius, Hege, Lorenz, Fryderyk, Nilsson, Lars, Rasmussen, Bengt, Lehmann, Sören, Hellström‐Lindberg, Eva, Jädersten, Martin, Ejerblad, Elisabeth

“…Summary The myelodysplastic syndromes (MDS) have highly variable outcomes and prognostic scoring systems are important tools for risk assessment and to guide…”
Get full text

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML by Mer, Arvind Singh, Heath, Emily M., Madani Tonekaboni, Seyed Ali, Dogan-Artun, Nergiz, Nair, Sisira Kadambat, Murison, Alex, Garcia-Prat, Laura, Shlush, Liran, Hurren, Rose, Voisin, Veronique, Bader, Gary D., Nislow, Corey, Rantalainen, Mattias, Lehmann, Soren, Gower, Mark, Guidos, Cynthia J., Lupien, Mathieu, Dick, John E., Minden, Mark D., Schimmer, Aaron D., Haibe-Kains, Benjamin

“…In acute myeloid leukemia (AML), molecular heterogeneity across patients constitutes a major challenge for prognosis and therapy. AML with NPM1 mutation is a…”
Get full text

MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia by Sanjiv, Kumar, Calderón-Montaño, José Manuel, Pham, Therese M, Erkers, Tom, Tsuber, Viktoriia, Almlöf, Ingrid, Höglund, Andreas, Heshmati, Yaser, Seashore-Ludlow, Brinton, Nagesh Danda, Akhilesh, Gad, Helge, Wiita, Elisee, Göktürk, Camilla, Rasti, Azita, Friedrich, Stefanie, Centio, Anders, Estruch, Montserrat, Våtsveen, Thea Kristin, Struyf, Nona, Visnes, Torkild, Scobie, Martin, Koolmeister, Tobias, Henriksson, Martin, Wallner, Olov, Sandvall, Teresa, Lehmann, Sören, Theilgaard-Mönch, Kim, Garnett, Mathew J, Östling, Päivi, Walfridsson, Julian, Helleday, Thomas, Warpman Berglund, Ulrika

“…Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, exhibiting high levels of reactive oxygen species (ROS). ROS levels have been suggested…”
Get full text

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry by Höglund, Martin, Sandin, Fredrik, Hellström, Karin, Björeman, Mats, Björkholm, Magnus, Brune, Mats, Dreimane, Arta, Ekblom, Marja, Lehmann, Sören, Ljungman, Per, Malm, Claes, Markevärn, Berit, Myhr-Eriksson, Kristina, Ohm, Lotta, Olsson-Strömberg, Ulla, Själander, Anders, Wadenvik, Hans, Simonsson, Bengt, Stenke, Leif, Richter, Johan

“…Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95%…”
Get full text

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population‐based study by Moreno Berggren, Daniel, Kjellander, Matilda, Backlund, Ellen, Engvall, Marie, Garelius, Hege, Lorenz, Fryderyk, Nilsson, Lars, Rasmussen, Bengt, Lehmann, Sören, Hellström‐Lindberg, Eva, Jädersten, Martin, Ungerstedt, Johanna, Ejerblad, Elisabeth

“…Summary Outcomes in chronic myelomonocytic leukaemia (CMML) are highly variable and may be affected by comorbidity. Therefore, prognostic models and…”
Get full text

Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia by Jacobsen, Sten Eirik W, Castor, Anders, Nilsson, Lars, Åstrand-Grundström, Ingbritt, Buitenhuis, Miranda, Ramirez, Carole, Anderson, Kristina, Strömbeck, Bodil, Garwicz, Stanislaw, Békássy, Albert N, Schmiegelow, Kjeld, Lausen, Birgitte, Hokland, Peter, Lehmann, Sören, Juliusson, Gunnar, Johansson, Bertil

“…The cellular targets of primary mutations and malignant transformation remain elusive in most cancers. Here, we show that clinically and genetically different…”
Get full text